Overview
Relapsing malignant neoplastic disease represents a significant clinical challenge, impacting millions globally and posing substantial burdens on healthcare systems. By 2050, projections estimate over 35 million new cancer cases annually, with high and very high Human Development Index countries like China experiencing notable increases in incidence [PMID:39317426]. The growing number of cancer survivors—currently over 14 million annually and projected to reach 22 million by 2040—underscores the critical need for effective long-term management strategies to improve quality of life and outcomes [PMID:28779220]. These patients often face complex symptomatology, including pain, fatigue, and anxiety, necessitating comprehensive care approaches that integrate symptom management, psychological support, and lifestyle interventions. Understanding the unique trajectories of disease progression and tailoring interventions accordingly is essential for optimizing patient care.
Epidemiology
The epidemiology of relapsing malignant neoplastic disease highlights a multifaceted burden on both patients and healthcare systems. Projections indicate a substantial rise in cancer incidence, particularly in economically advanced regions, where lifestyle factors and aging populations contribute significantly to this trend [PMID:39317426]. The increasing number of cancer survivors emphasizes the importance of addressing long-term health issues, including comorbidities such as hypertension, obesity, mental health disorders, and chronic heart disease, which collectively affect over 70% of cancer survivors in the UK and are linked to higher risks of recurrence and mortality [PMID:28779220]. These comorbidities not only complicate treatment but also necessitate integrated care models that address both the primary malignancy and secondary health concerns. Additionally, cultural factors play a crucial role, especially in regions like Asia, where discussions about prognosis and palliative care are influenced by societal norms and expectations, impacting patient communication and care planning [PMID:34039322].
Clinical Presentation
Patients with relapsing malignant neoplastic disease often present with a constellation of symptoms that significantly impact their quality of life. Pain, a prevalent issue affecting up to 66% of patients, particularly in terminal stages, is frequently compounded by fatigue and anxiety [PMID:39317426]. These symptoms can manifest in distinct disease trajectories, characterized by periods of relative stability followed by rapid decline, contrasting with the more predictable gradual decline seen in non-cancer chronic conditions like congestive heart failure or end-stage renal disease [PMID:34039322]. The psychological impact is profound, with many patients maintaining an optimistic outlook that may not align with clinical assessments, as evidenced by studies showing discrepancies between patient and physician perceptions of health status [PMID:33549021]. Furthermore, oncological treatments often lead to reduced physical activity levels due to side effects and lack of supportive guidance, underscoring the need for structured exercise programs and behavior change interventions to enhance patient resilience and well-being [PMID:31441015].
Diagnosis
Diagnosing relapsing malignant neoplastic disease involves a comprehensive evaluation that considers both clinical and prognostic indicators. Prognostic tools, such as Performance Status (PPS) scales, are widely utilized but require validation within specific populations to ensure accuracy and utility [PMID:34039322]. The predictive accuracy of these tools can vary between cancer and non-cancer patients, necessitating tailored validation studies to improve their applicability in clinical settings. Additionally, understanding tumor-specific growth rates and repopulation dynamics is crucial for predicting symptom relief and guiding treatment decisions, particularly in palliative care contexts [PMID:12573761]. Effective diagnosis also hinges on accurate symptom assessment and patient-reported outcomes (PROs), which can reveal unmet needs and distress levels not fully captured by clinical evaluations alone [PMID:36641450]. Integrating these multifaceted assessments helps clinicians tailor interventions more precisely to individual patient needs.
Management
The management of relapsing malignant neoplastic disease encompasses a holistic approach aimed at alleviating symptoms, enhancing quality of life, and improving functional outcomes. Digital health interventions, including mobile applications, telehealth, and wearable sensors, are increasingly pivotal in monitoring and managing symptoms such as pain, fatigue, and anxiety [PMID:39317426]. These technologies facilitate real-time data collection, enabling timely interventions and personalized care plans. Patient-reported outcome measures (PROMs) are essential for identifying unmet needs and evaluating treatment efficacy, although their implementation requires robust support from healthcare leadership and staff buy-in to overcome skepticism about feasibility and benefits [PMID:36641450]. Exercise interventions, supported by behavior change techniques like social support and goal-setting, have shown significant improvements in physical activity levels, quality of life, and reductions in anxiety and fatigue among cancer survivors [PMID:31441015]. Furthermore, leveraging lay health workers (LHWs) to screen for and manage symptoms can lead to reduced emergency department visits and hospitalizations, highlighting the value of community-based support systems [PMID:32176306]. Advanced technologies, such as convolutional neural networks (CNNs) applied to symptom logs, offer promising avenues for predicting symptom escalations and enabling proactive management [PMID:40200443].
Symptom Management
Effective symptom management is central to improving patient outcomes in relapsing malignant neoplastic disease. Working Group 3 emphasizes the importance of integrating evidence-based practices through implementation science to ensure that symptom management strategies are consistently applied in clinical routines [PMID:40803757]. Digital health solutions, including telemedicine and wearable devices, are increasingly recognized for their role in continuous monitoring and timely intervention, thereby reducing acute care utilization and enhancing patient comfort [PMID:39317426]. Additionally, structured palliative care interventions, such as nurse-led consultations and interprofessional case conferences, aim to optimize symptom control and support holistic patient care, although their cost-effectiveness remains an area of ongoing research [PMID:37872126]. The use of PROMs not only aids in identifying unmet needs but also fosters better communication between patients and healthcare providers, bridging gaps in understanding and care [PMID:36641450].
Psychological and Social Support
Psychological and social support are integral components of managing relapsing malignant neoplastic disease. Patients often experience significant psychological distress, including anxiety and depression, which can be mitigated through targeted interventions and support systems [PMID:33549021]. Communication practices in palliative care are evolving, with a growing trend towards direct patient involvement in receiving critical health information, reflecting a shift towards patient-centered care [PMID:25880541]. Family caregivers also play a crucial role, with interventions like the ONDIARY program showing sustained improvements in caregiver quality of life [PMID:34781203]. Understanding and addressing the psychological determinants of behavior change, such as self-efficacy and autonomy, can significantly enhance patient adherence to exercise regimens and other lifestyle modifications [PMID:31441015].
Complications
Relapsing malignant neoplastic disease often leads to a range of complications that exacerbate patient morbidity and healthcare utilization. Unmanaged symptoms frequently result in unplanned hospital admissions, underscoring the critical need for proactive symptom management strategies [PMID:39317426]. Comorbidities, including cardiovascular disease and mental health issues, are prevalent among cancer survivors and contribute to increased risks of recurrence and mortality [PMID:28779220]. Data from patient-reported outcome measures (PROMs) frequently reveal distress levels that clinicians may underestimate, highlighting the importance of these tools in uncovering additional clinical insights and guiding more nuanced care plans [PMID:36641450]. Furthermore, uncontrolled symptoms are linked to higher healthcare costs and increased reliance on acute care services, emphasizing the economic burden alongside the clinical impact [PMID:32176306].
Prognosis & Follow-up
Prognostication in relapsing malignant neoplastic disease involves balancing clinical assessments with patient-reported outcomes to provide accurate survival estimates and guide treatment planning. Performance Status (PPS) scales, while widely used, show varying predictive accuracy across different patient populations, necessitating local validation studies for improved utility [PMID:34039322]. Digital health technologies offer promising tools for continuous monitoring, potentially improving patient outcomes through timely interventions based on symptom trends [PMID:39317426]. Exercise and physical activity post-diagnosis have been linked to improved survival rates and reduced recurrence risks, particularly in breast and colorectal cancer survivors, underscoring the importance of maintaining an active lifestyle [PMID:28779220]. Regular follow-up care should incorporate both clinical assessments and patient feedback to ensure comprehensive management and address evolving needs effectively.
Special Populations
Special considerations are necessary for diverse patient populations experiencing relapsing malignant neoplastic disease. In culturally diverse settings, such as Thailand, discussions around prognosis and palliative care are deeply influenced by cultural norms, affecting communication and care planning [PMID:34039322]. Lay health workers (LHWs) have demonstrated effectiveness in managing symptoms across various stages of cancer, suggesting broad applicability in diverse populations [PMID:32176306]. Cancer survivors often face increased risks of comorbidities due to treatment-related toxicities and shared risk factors like obesity, necessitating integrated care approaches that address both cancer and secondary health issues [PMID:28779220]. Additionally, psychological and social support tailored to specific cultural contexts can significantly enhance patient and caregiver well-being, as evidenced by interventions like the ONDIARY program [PMID:34781203].
Key Recommendations
References
1 Colomer-Lahiguera S, Pozzar RA, Harris CS, Brant JM, Conley YP, Cooley ME et al.. Advancing Global Cancer Symptom Science: Insights and Strategies from the Inaugural Cancer Symptom Science Expert Meeting. Seminars in oncology nursing 2025. link 2 Hamdoune M, Jounaidi K, Ammari N, Gantare A. Digital health for cancer symptom management in palliative medicine: systematic review. BMJ supportive & palliative care 2024. link 3 Müller E, Mayer-Steinacker R, Gencer D, Keßler J, Alt-Epping B, Schönsteiner S et al.. Feasibility, use and benefits of patient-reported outcome measures in palliative care units: a multicentre observational study. BMC palliative care 2023. link 4 Prompantakorn P, Angkurawaranon C, Pinyopornpanish K, Chutarattanakul L, Aramrat C, Pateekhum C et al.. Palliative Performance Scale and survival in patients with cancer and non-cancer diagnoses needing a palliative care consultation: a retrospective cohort study. BMC palliative care 2021. link 5 Patel MI, Ramirez D, Agajanian R, Agajanian H, Coker T. Association of a Lay Health Worker Intervention With Symptom Burden, Survival, Health Care Use, and Total Costs Among Medicare Enrollees With Cancer. JAMA network open 2020. link 6 Mazzoni AS, Carlsson M, Berntsen S, Nordin K, Demmelmaier I. "Finding my own motivation" - A Mixed Methods Study of Exercise and Behaviour Change Support During Oncological Treatment. International journal of behavioral medicine 2019. link 7 Roberts AL, Fisher A, Smith L, Heinrich M, Potts HWW. Digital health behaviour change interventions targeting physical activity and diet in cancer survivors: a systematic review and meta-analysis. Journal of cancer survivorship : research and practice 2017. link 8 Colomer-Lahiguera S, Pozzar RA, Harris CS, Brant JM, Conley YP, Cooley ME et al.. Advancing Global Cancer Symptom Science: Insights and Strategies From the Inaugural Cancer Symptom Science Expert Meeting. Cancer nursing 2025. link 9 Pedreira NP, Costa ETT, Costa de Castro C, Rodrigues GAD, Pedreira NP, Ramos GMG et al.. Satisfaction with nursing care among patients with cancer receiving palliative care in a hospital. International journal of palliative nursing 2025. link 10 Finkelstein J, Smiley A, Echeverria C, Mooney K. Leveraging Convolutional Neural Networks for Predicting Symptom Escalation in Chemotherapy Patients: A Temporal Resampling Approach. Studies in health technology and informatics 2025. link 11 Gottschalk S, König HH, Mallon T, Schulze J, Weber J, Böttcher S et al.. Cost-effectiveness of a specialist palliative care nurse-patient consultation followed by an interprofessional case conference for patients with non-oncological palliative care needs: results of the KOPAL trial. Annals of palliative medicine 2023. link 12 Ito E, Tadaka E. Effectiveness of the Online Daily Diary (ONDIARY) program on family caregivers of advanced cancer patients: A home-based palliative care trial. Complementary therapies in clinical practice 2022. link 13 Koontz BF, Levine E, McSherry F, Niedzwiecki D, Sutton L, Dale T et al.. Increasing physical activity in Cancer Survivors through a Text-messaging Exercise motivation Program (ICanSTEP). Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2021. link 14 Barnato AE, Khayal IS. The power of specialty palliative care: moving towards a systems perspective. The Lancet. Haematology 2021. link00099-5) 15 Hiratsuka Y, Oishi T, Miyashita M, Morita T, Mack JW, Takahashi M et al.. Patients' understanding of communication about palliative care and health condition in Japanese patients with unresectable or recurrent cancer: a cross-sectional survey. Annals of palliative medicine 2021. link 16 Sprague SL, Holschuh C. Telemedicine Versus Clinic Visit: A Pilot Study of Patient Satisfaction and Recall of Diet and Exercise Recommendations From Survivorship Care Plans. Clinical journal of oncology nursing 2019. link 17 Ichikura K, Matsuda A, Kobayashi M, Noguchi W, Matsushita T, Matsushima E. Breaking bad news to cancer patients in palliative care: A comparison of national cross-sectional surveys from 2006 and 2012. Palliative & supportive care 2015. link 18 Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. The Lancet. Oncology 2014. link70578-3) 19 Jones B, Cominos M, Dale RG. Application of biological effective dose (BED) to estimate the duration of symptomatic relief and repopulation dose equivalent in palliative radiotherapy and chemotherapy. International journal of radiation oncology, biology, physics 2003. link04284-0) 20 Pandey M, Thomas BC. Rehabilitation of cancer patients. Journal of postgraduate medicine 2001. link
20 papers cited of 27 indexed.